Quantitative definition and monitoring of the host cell protein proteome using iTRAQ – a study of an industrial mAb producing CHO-S cell line by Chiverton LM et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a Creative Commons Attribution 4.0 International License 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Chiverton LM, Evans C, Pandhal J, Landles AR, Rees BJ, Levison PR, Wright PC, 
Smales M.  
Quantitative definition and monitoring of the host cell protein proteome 
using iTRAQ – a study of an industrial mAb producing CHO-S cell line. 
Biotechnology Journal 2016 
DOI: http://dx.doi.org/10.1002/biot.201500550 
 
 
Copyright: 
© 2016 The Authors. Biotechnology Journal published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. 
This is an open access article under the terms of the Creative Commons Attribution License, which 
permits use, distribution and reproduction in any medium, provided the original work is properly cited. 
DOI link to article: 
http://dx.doi.org/10.1002/biot.201500550  
Date deposited:   
29/06/2016 
	 Biotechnol.	J.	2016,	11	 DOI	10.1002/biot.201500550
www.biotechnology-journal.com
Biotechnology
Journal
1
© 2016 The Authors. Biotechnology Journal published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.  
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,  
distribution and reproduction in any medium, provided the original work is properly cited.
1    Introduction
Monoclonal antibodies (mAbs) constitute the largest class 
and number of biotherapeutic recombinant proteins cur-
rently on the market [1]. The Chinese hamster ovary (CHO) 
cell is preferentially utilized for the production of recombi-
nant mAbs due to their ability to produce correctly folded 
and assembled mAb with human-like glycans [2–4]. The 
mAbs are secreted into the harvest cell culture fluid 
(HCCF) during fermentation and recovered from this dur-
ing downstream processing to separate the required mAb 
from process (e.g. host cell proteins [HCPs], DNA, RNA, 
lipids and other cellular derived material) and product (e.g. 
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mAb fragments, aggregates) impurities [5]. HCPs found in 
the HCCF can be derived either from secreted endogenous 
CHO proteins or released into the cell culture supernatant 
upon cell lysis, including during collection of the harvest 
material. A number of studies have suggested that cell 
viability at harvest is a critical aspect in determining the 
number and presence of those HCPs present in the down-
stream processing feedstock (see [6–7] for reviews). Whilst 
there is no precise specification for total HCP content in 
final biotherapeutic preparations, with preparations being 
judged on a case-by-case basis [8], generally the literature, 
industry and regulatory authorities work towards HCP 
limits of 1–100 ppm (1–100 ng HCP per mg biotherapeutic 
protein) in the final product [9]. HCPs remaining in bio-
therapeutic recombinant proteins potentially present a 
risk to the patient [9–11], the major potential risk sug-
gested to be that of immunogenicity [12].
A number of studies have now reported on the moni-
toring of HCPs during process development of biothera-
peutic proteins, including mAbs, in order to inform about 
the development of, and validate, such processes. The 
downstream purification of mAbs from CHO cell culture 
harvest fluid is heavily reliant upon depth filtration and 
chromatographic approaches to remove process and 
product impurities. A ‘typical’ downstream purification 
process for mAbs includes an initial Protein A chromatog-
raphy step, often followed by a low pH hold viral inactiva-
tion step, followed by one or two more polishing steps and 
an additional viral filtration step before the product is 
concentrated and formulated for use in the clinic [13]. For 
mAbs, key studies have now been published showing 
that the specific interaction of HCPs with the product dur-
ing Protein A affinity chromatography results in particular 
HCPs co-eluting with the mAb [14]. Therefore, the prod-
uct makes a significant contribution to defining the HCPs 
that co-elute with the mAb [15].
The dynamic range of HCP concentrations in the cell 
culture harvest material, and throughout downstream 
processes, means that not any one technology is able to 
detect and monitor all those HCPs present. Multi-analyte 
ELISA is the current workhorse approach adopted 
throughout the industry to measure and monitor HCP 
content/concentration due to its high throughput nature, 
selectivity and sensitivity [9, 16]. However, there are limi-
tations to the ELISA approach, therefore the use of 
orthogonal methods to support process development and 
validation is recommended [9]. The major orthogonal 
approaches that have emerged to monitor/measure HCPs 
are 2D-PAGE [17], particularly 2D-DIGE [18–19], and mass 
spectrometry [14, 20–24]. These approaches give informa-
tion on the specific nature/identification of those HCPs 
present during up-stream and downstream processing, 
allowing clearance and risk to be assessed on the nature 
of those HCPs present, rather than on the combined con-
centration of HCPs [7]. Indeed, a recent report suggests 
that the application of LC-MS/MS approaches could be 
applied to overcome limitations of the ELISA and 2D-PAGE 
approaches for HCP monitoring [16]. Such an approach 
has been applied to the profiling of downstream HCPs in 
therapeutic peptibodies expressed in Escherichia coli, 
demonstrating how process changes influenced subse-
quent residual HCP content and makeup [25]. 
The use of combined orthogonal approaches, includ-
ing mass spectrometry, to monitor HCPs from CHO cell 
cultures has now been reported by a number of groups. 
For example, Pezzini et al. [26] demonstrated how condi-
tions for ‘optimal’ mixed mode chromatography purifica-
tion of mAbs from CHO cell culture harvest material can 
be determined by utilizing Design of Experiment mode-
ling approaches combined with mass spectrometry anal-
ysis to identify those HCPs co-purifying with the target 
mAb. The differences in selectivity and efficiency of clas-
sical versus multimodal cation exchange chromatogra-
phy for mAb purification with respect to those HCPs 
retained in the mAb fraction have also been demonstrat-
ed by mass spectrometry [22]. A comparison of the HCP 
profile of three null CHO cell lines using ELISA, 2D-PAGE 
and LC-MS/MS approaches indicated that the HCPs in 
different feedstocks for downstream processing were not 
as diverse as might have been expected [16]. Indeed, 
reports suggest that it is a subset of the total HCP profile 
present in CHO cell culture supernatants that are more 
difficult to purify or remove during downstream process-
ing, as they interact with chromatography media and/or 
co-purify with the target product [27]. Valente et al. used 
a combination of 2D-electrophoresis and shotgun prot-
eomic approaches to demonstrate that the cell age 
impacts upon the extracellular CHO HCP profile, identify-
ing specific proteins whose expression profile changes 
with culture time [28]. Zhang and colleagues further dem-
onstrated the potential of mass spectrometry for monitor-
ing HCPs during process change, tracking HCPs from the 
HCCF through to  Protein A eluate and further down-
stream, identifying around 500 HCPs in the HCCF, follow-
ing these until no HCPs were identified in the final cation-
exchange chromatography eluate [24]. 
Here, we use iTRAQ non-gel based LC-MS/MS pro-
teomic profiling to enhance the coverage of HCPs 
detected beyond standard 2D-PAGE [8], and apply 
quantitative mass spectrometry to define the harvest 
supernatant HCP proteome of a mAb producing CHO-S 
host cell line, and follow the HCP profile during a stand-
ard downstream mAb purification following expression 
in a fed-batch 100 L wave bioreactor. We have used this 
approach to characterize and profile the HCPs in the 
harvest cell culture fluid (HCCF), and to follow the fate 
of each HCP throughout downstream processing (DSP) 
using a typical purification process. iTRAQ was imple-
mented in two workflow formats: to analyze DSP by 
Protein A chromatography (six sample analysis) and 
Protein A followed by additional chromatographic cati-
on and anion exchange steps (eight sample analysis). 
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These data indicate that the majority, if not all, HCPs 
detectable in the HCCF are detectable throughout the 
whole of the downstream process examined, albeit at 
very much reduced amounts. The enrichment of spe-
cific HCPs as a percentage of the total throughout the 
downstream process is also evident.
2    Materials and methods
All materials and reagents were sourced from Sigma-
Aldrich, UK, unless otherwise stated.
2.1     Cell culture of a model CHO-S mAb producing 
cell line and preparation of the HCCF  
for downstream processing.
The model CHO-S mAb producing cell line had previ-
ously been engineered to stably express a model IgG1 
mAb against HER2 (human epidermal growth factor 
receptor 2) and was cultured at Pall Life Sciences (Ports-
mouth, UK). For the 100  L single-use rocker bioreactor 
experiment, the culture was inoculated with 2.3 × 105 
viable cells per mL from an exponentially growing seed 
train culture in CD1000 media (BD Biosciences) supple-
mented with 30% CHO CD Efficient Feed™ A AGT™ 
(Invitrogen), 1.47 g/L sodium bicarbonate, 8  mM L-glu-
tamine, 0.5% w/v Boost 4 (Hyclone) and 1.0 g/L pluronic 
F86. The cell number and viability were monitored 
throughout culture using a Vi-Cell instrument (BD). At 
374  h of culture (viability 52%), the harvest cell culture 
fluid (HCCF) was collected by centrifugation.
2.2    Protein A chromatography
HCCF was loaded onto a prepacked HiTrap®  MabSelect™ 
SuRe™ column (1 mL, GE Healthcare, Little Chalfont, UK) 
with the pressure threshold set at 0.5 MPa. The column 
was equilibrated with 10 column volumes (CVs) of 20 mM 
sodium phosphate pH 6.8 at a flow rate of 1 mL/min and 
the sample then loaded at 2.5  mL/min and the flow-
through collected. The column was washed with 5 CVs of 
20 mM sodium citrate, pH 5 and the mAb then eluted with 
3 CVs of 20 mM sodium citrate, pH 3.5 and the eluate col-
lected. For HCCF subjected to Protein A affinity chroma-
tography only, samples were run in 5 × 10 mL lots through 
the column, and then all eluate fractions combined. For 
the experiment analyzing HCCF, Protein-A eluate, and 
then subsequent post-cation and anion exchange mate-
rial, 150 mL of HCCF was subjected to Protein A affinity 
purification in 15 × 10 mL runs with the subsequent elu-
ates combined after each step. The mAb containing frac-
tions were then pooled for further downstream process-
ing, with a sample of the pooled fractions retained for 
subsequent HCP analysis.
2.3    Cation exchange chromatography
The combined pooled volume of post-Protein A eluate 
(45 mL) was loaded onto a 5 mL prepacked S HyperCel™ 
column (Pall Life Sciences, Portsmouth, UK) witha pres-
sure threshold of 0.5 MPa and a flow rate of 1 mL/min. The 
column was equilibrated with 10 CVs of 20 mM sodium 
citrate, pH 3.75 and the sample then loaded onto the col-
umn at 2.5 mL/min. The column was washed with 5 CVs 
of 20 mM sodium citrate, pH 3.75. The mAb was eluted 
with 6 CVs of 20 mM sodium phosphate, pH 7, followed 
by a 5  CV 10  min gradient from 100% 20  mM sodium 
phosphate, pH 7, to 100% 20 mM sodium phosphate/1 M 
sodium chloride at 2.5 mL/min. The eluate was kept for 
anion exchange chromatography. 
2.4    Anion exchange chromatography
Acrodisc Mustang Q, 1  mL format (Pall Life Sciences, 
Portsmouth, UK) was used for anion chromatography of 
the post-cation exchange eluate. Preparation of the mem-
brane disc for use was undertaken by washing with 4 mL 
of 1 M sodium hydroxide followed by washing with 4 mL 
of 1  M sodium chloride. The sample was then passed 
through the column and the flow-through collected. 
2.5    2D-PAGE analysis of HCPs
2D-PAGE analysis was undertaken as previously described 
[6, 29, 30]. 
2.6    HCP ELISA
HCP concentrations were determined in samples using 
the commercially available ELISA kit from Cygnus Tech-
nologies. The concentration of HCPs present in samples 
was then determined from a standard curve as previously 
described [30].
2.7     Sample preparation for iTRAQ proteomic 
analysis, HILIC-HPLC fractionation,  
mass spectrometry analysis, proteomic data 
identification, and proteomic data analysis
Mass spectrometry sample preparation, experimental 
setup and data analysis were all undertaken following 
standard procedures as described in detail in the Support-
ing information, Methods file S1. Due to the size and cost 
of the 100 L wavebag experiments, technical replicates 
were analyzed by the iTRAQ proteomic approach.
2.8    Pathways analysis
Pathway analysis was performed using UniProtKB for 
Gene Ontology analysis. The freeware software Panther 
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(www.pantherdb.org) was used for classification of iden-
tified proteins into functional classes.
2.9    Heatmaps
Heatmaps were generated using an R software package 
(see Warnes, G. R., Bolker, B., Bonebakker, L., Gentleman, 
R. et al., gplots: Various R programming tools for plotting 
data. R package version 2.12.1; http://CRAN.R-project.
org/package=gplots2013).
3    Results
3.1     Recombinant mAb production, purification 
and determination of HCP concentrations 
throughout the downstream process by 
commercial HCP ELISA, SDS- and 2D-PAGE
We used a mAb expressing CHO cell line, cultured in a 
100 L Single-Use rocker bioreactor, as a model system to 
investigate the CHO-S host cell protein proteome and 
how this changes through a standard mAb chromato-
graphic downstream process. As described in the intro-
duction, whilst the required mAb is secreted into the 
culture supernatant, endogenous CHO proteins can also 
be released via secretion out of the cell or during lysis/
breakage of cells during culture and/or harvesting. Here, 
we applied iTRAQ proteomic profiling as a discovery tool 
to provide a broad quantitative analysis of the CHO HCP 
proteome and how this changes throughout a standard 
mAb downstream process. The HCCF from our model 
system was harvested after 374 h of culture when culture 
viability in the wavebag began to decline (Fig. 1A). The 
antibody concentration in the HCCF at this time was 
determined as 1.69  g/L (Fig.  1B), with the cell specific 
productivity during exponential growth phase, being 
21 pg/cell/day.
After collection of the HCCF, we subjected this to a 
typical mAb downstream chromatographic purification 
process for subsequent HCP and proteomic analysis. Two 
purifications of the HCCF material were undertaken for 
two different iTRAQ HCP profiling experiments. For the 
first experiment, the HCCF was subjected to an initial 
primary purification step, consisting of a Protein A affinity 
chromatography step, and the flow-through and eluate 
collected. The second experiment analyzed HCCF and 
samples from three sequential downstream processing 
steps: eluates from Protein A and cation exchange chro-
matography and the flow-through from anion exchange. 
Samples were also stored and prepared for HCP ELISA 
and 2D-PAGE analysis, the results of which are shown in 
Figs. 2 and 3. A total of 75 µg of total protein from each 
fraction was analyzed by iTRAQ-based protein profiling 
with the workflows shown in Supporting information, 
Fig.  S1. The commercial HCP ELISA methodology is 
based upon immune-detection using anti-HCP antibod-
ies. The HCP ELISA data are shown for the six sample and 
eight sample experiments in Fig. 2. Figure 2A shows the 
HCP concentration, as determined from the ELISA data in 
the HCCF, and, subsequently, that in the Protein A flow-
through and eluate fractions. The concentration of HCP in 
the HCCF is approximately equivalent to that of the mAb, 
meaning there is an approximate 50:50 mix of mAb and 
HCP in the cell culture supernatant material. Almost all of 
the HCPs (>99%) were removed by the Protein A chroma-
tography step as determined by the HCP ELISA, with the 
majority of HCPs being found in the flow-through fraction. 
The concentration of HCP in the eluate was <10 ppm as 
determined using the commercially available HCP assay 
(Fig. 2A). This was also observed in the samples gener-
ated for the eight sample experiment, with the subse-
quent cation and anion exchange steps used in this 
experiment making a small, but insignificant, difference 
to the total amount of HCP present in these samples 
(Fig.  2B). However, these data provide no information 
about which HCPs remained as the purification process 
progressed, and whether all HCPs were reduced in con-
centration, or if some were concentrated along with the 
mAb. 
Reduced SDS-PAGE and 2D-PAGE analysis was then 
undertaken on the HCCF, Protein A flow-through and 
Protein A eluate samples generated from the six sample 
Figure 1. Viable cell number, culture viability and antibody concentration 
data during the CHO-S mAb producing cell line fed-batch 100 L single-use 
rocker culture. (A) viable cell numbers (squares, n) and associated cell 
viability (triangles, p) across the fermentation. (B) mAb concentration in 
the cell culture supernatant throughout culture. The harvest cell culture 
fluid (HCCF) was harvested for analysis of HCPs at 374 h.
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experiment (Fig. 3). These analyses again confirmed the 
enrichment of the recombinant mAb heavy and light 
chains in the Protein A eluate, and that they were also 
both present in the flow-through fraction (Fig.  3A). 
2D-PAGE analysis clearly showed the concentration of 
the heavy and light chain in the Protein A eluate and 
depletion of HCPs in this fraction, with the majority of 
HCPs observed in the Protein A flow-through fraction. In 
each case, the heavy and light chain polypeptides are the 
most intense bands/spots on the gel, at 50 kDa and 25 kDa 
(Fig.s 3B–D) respectively, as the gels are run under reduc-
ing conditions. The presence of other protein spots on the 
gels likely correspond to HCPs, visible in the HCCF and 
post-Protein A flow-through. However, these spots are 
not visible using Coomassie stain in the post-Protein A 
eluate, and mAb dominates and obscures the gel image. 
This justifies the need for alternative analyses for the pres-
ence of HCPs co-enriching with mAb in such samples. 
Although western blot analysis of 2D-PAGE can be under-
taken using anti-HCP antibodies, this does not allow 
identification of specific HCPs, and, hence, we applied 
the non-gel based iTRAQ proteomic approach as a dis-
covery tool to monitor and identify HCPs present in the 
HCCF and throughout the downstream purification pro-
cess.
3.2     iTRAQ proteomic profiling of CHO HCPs 
throughout a standard mAb downstream 
purification process
The proteome at each stage of the downstream purifica-
tion process was analyzed (in technical replicates) using 
quantitative proteomics. In this regard the approach we 
have taken mimics that for a ‘production run’ generating 
clinical material, where each batch of product generated 
is done in a single run after which the HCP profile is 
required to be detailed without the ability to analyze bio-
logical replicates. The iTRAQ approach used here was 
favored over gel-based methods, as it has the capacity to 
identify proteins based on their primary sequence – rath-
er than mass or isoelectric point – at a far higher level of 
sensitivity [7]. It also complements the HCP ELISA exper-
iment, as it has the capacity to detect proteins that do not 
elicit an immune response. For quantitative proteomic 
analysis, the isobaric tagging strategy iTRAQ was used. 
This methodology enables simultaneous identification 
and relative quantification of proteins, in multiplex for-
mat, of up to eight samples within a single experimental 
run [31]. 
As described in the Methods section, 8-plex iTRAQ 
was implemented in two workflow formats, employing 
either six samples (with two labels reserved for noise mod-
eling) or eight samples, as demonstrated in (Supporting 
information, Fig. S1). The six sample iTRAQ experiment 
was directed to analyze technical replicates of three sam-
ples, which were HCCF, Protein A flow-through and Pro-
tein A eluate (Supporting information, Fig. S1A). The eight 
sample format was used to analyze technical replicates of 
four sample types: HCCF compared to Protein A eluate 
and subsequent cation and anion exchange purification of 
the Protein A eluate (Supporting information, Fig.  S1B). 
The data were processed for protein identification and 
relative quantification. The list of proteins identified are 
reported in Supporting information, Tables S1 and S2.
In the six sample iTRAQ experiment, 8781 spectra 
were confidently matched to peptides from 819 proteins 
(including the mAb chains). Across both the six and eight 
sample experiments 936 proteins were identified. In the 
eight sample comparison, 4187 spectra were confidently 
matched to peptides from 219 proteins. The reduced 
number of identifications in the eight sample iTRAQ, rela-
tive to the six sample experiment, occurred due to mAb 
dominance in the sample, leading to a stochastic reduc-
tion in the identification of HCP peptides. This resulted in 
83.4% of the peptide spectral match (PSM) being matched 
to mAb derived peptides; for comparison, mAb derived 
peptides contributed only 47% of PSM in the six sample 
analysis. The same replicates of HCCF were used on both 
experiments, providing a common sample to link analy-
Figure 2.  HCP analysis determined by ELISA of HCCF and samples during 
DSP. HCP concentrations were determined using commercially available 
ELISA for (A) HCCF, Protein A flow-through, Protein A eluate, and  
(B) HCCF and eluates from sequential processing by Protein A, Cation 
exchange and anion exchange steps. Data are ± standard error of mean, 
n = 2 technical replicates.
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ses. Of the 219 proteins identified in the eight sample 
iTRAQ, 100 were common to the six sample iTRAQ; all 
219 proteins identified to a three or more unique peptide 
confidence in the eight sample analysis were present in 
the six sample comparison. Interestingly, proteins identi-
fied and retained include proteases such as cathepsins 
and serine proteases, such molecules having previously 
been shown to result in degradation of mAbs after purifi-
cation [32–34], and thioredoxin reductase, which has 
been identified as playing a major role in the reduction of 
intact mAb in cell culture supernatants [35, 36]. 
3.3    Global quantification analysis of mAb and HCP
By normalizing the protein quantitations by channel sum, 
each iTRAQ label was scaled so that the sum of all report-
er ion intensities were evaluated as equal, enabling esti-
mation of the global concentrations of HCPs and mAb 
within the sample. As expected, this method showed 
reducing global levels of HCP relative to mAb during Pro-
tein A chromatography in both iTRAQ experiments 
(Figs. 4A, 4B and 5A). The relative change of individual 
proteins across the purification steps is presented in heat-
map format (Figs. 4 and 5).
An interesting observation from the 8-plex iTRAQ 
data was an alteration in the ratio of heavy (HC) to light 
(LC) chains of the mAb (Supporting information, Table S3). 
This was calculated by balancing the HC and LC ratios to 
be even at the reference label – in this case in the Protein 
A eluate – and then observing how the relative quantifica-
tions changed after each progressive purification step. In 
the HCCF samples, there is a 2:1 ratio of LC to HC mAb. 
However, this balances out after Protein A chromatogra-
phy. The change from the HCCF to the Protein A eluate is 
not surprising, as this step should remove free LC and LC 
dimers that are present in the HCCF – resulting from the 
Protein A column binding of the HC species only (note 
that there is no Protein A flow-through in this experiment, 
where the LC would be observed). The progressive reduc-
tion in the ratio of HC to LC in the following chromatogra-
phy steps may indicate the removal of un-bound HC, or 
could be indicative of degradation of the mAb complex.
3.4     Quantitative analysis of HCPs during 
downstream purification
As detailed in the Methods section, we approached the 
data analysis in two stages. HCPs detectable above the 
noise-level at each stage of purification were determined. 
The mean iTRAQ ratio was determined if the relative 
amount of protein had reduced/increased as a conse-
quence of DSP. Finally, we merged these two analyses  to 
Figure 3.  Reduced PAGE analysis of pro-
tein profiles of the HCCF of the CHO-S 
mAb producer, Protein A eluate and 
post-Protein A flow-through. (A) 1D 
SDS-PAGE Gel (two replicates of each 
condition, 5 µg total protein per sample 
loaded) analysis of samples. H, harvest; 
FT, Protein A flow through; E, Protein A 
elute. (B–D) 2D-PAGE analysis of 100 µg 
of total protein from the HCCF (B), Pro-
tein A flow-through (C) and Protein A 
eluate (D) material visualized using 
Coomassie Blue stain. Red arrows 
 indicate the presence of heavy and  
light chains at 50 kDa and 25 kDa 
respectively.
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Figure 4.  Quantitative proteomic analysis of Protein A purification. (A) Stacked bar chart of relative amounts of mAb and HCP based on iTRAQ reporter 
ion intensity values as a proportion of the total. HCP and mAb shown in red and blue respectively. (B) Relative distribution of HCP during Protein A chro-
matography, protein ratios are calculated from individual peptide intensity values divided by the mean of all intensities. (C) Two color heatmap: rows repre-
sent individual proteins identified and relatively quantified by three or more unique peptides, columns represent the individual samples. The intensity scale 
is brightest green, black, brightest red, where green indicates relative decrease and red increase in protein level. (D) Heatmap where rows represent indi-
vidual proteins identified and relatively quantified by three or more peptides, columns represent the individual samples. Intensity scale green, black, red, 
with red indicating increase and green decrease. Data are shown for the HCCF starting material and the Protein A eluates. Protein heavy (X000002) and 
light (X000001) chains are highlighted with blue arrows. The row z score (turquoise) is calculated by centering the rows, scaled by subtracting the mean  
of the row from every value and then dividing the resulting values by the standard deviation of the row.
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generate three lists of proteins for each purification step: 
proteins that were above the limit of detection, proteins 
that were either preferentially retained or decreased rela-
tive to the previous stage (Supporting information, 
Table  S4). This analysis focused on proteins with data 
from three or more unique peptides in order to ensure 
robust quantification data.
In the six sample experiment, all proteins were detect-
able in the Protein A flow-through, with 86 HCPs at detect-
able levels in the Protein A eluate. Of these 86 detectable 
proteins, two were preferentially retained, i.e. increased 
relative to HCCF starting material, and these were Protea-
some subunit alpha type and Ubiquitin activating enzyme 
E1 (Uniprot accession numbers G3I9G7 and G3IBG3 
respectively). In the eight sample experiment, in addition 
to the mAb, six HCPs proteins were detectable in the 
Protein A eluate, with five in common to those observed 
with the six sample experiment directed to Protein A 
purification. These proteins were Peroxiredoxin-1, fruc-
tose bisphosphate aldolase, 78  kDa glucose regulated 
protein, pyruvate kinase and Cathepsin Z (Uniprot acces-
sion numbers G3GYP9, G3I3X4, G3I8R9, G3IAX3, 
Q9EPP7). Strikingly, Peroxiredoxin-1, a redox regulatory 
protein (Uniprot accession number G3GYP9) was detect-
able in the anion exchange flow-through. Further analysis 
revealed that this protein was also present in the cation 
exchange eluate, identified and relatively quantified with 
two unique peptides. The data suggest that Peroxire-
doxin-1 is retained during the three stage DSP, but its 
level was decreased relative to the Protein A eluate.
4    Discussion
The International Conference on Harmonisation Guide-
line Q11 on the development and manufacture of drug 
substances 2012 suggests HCPs are a critical quality 
attribute (CQA) [37]. Although there have been a num-
ber of reports that identify and monitor HCPs during 
the bioprocessing of CHO produced biopharmaceuti-
cals, the majority of approaches utilized do not allow for 
the identification of specific individual HCPs, or follow 
their fate during an entire downstream process. This 
makes a thorough risk-based analysis of the HCP com-
ponent of the end product difficult, and the concentra-
tion of HCPs alone may mask small amounts of high-
Figure 5.  Quantitative proteomic analysis of three stage downstream 
process. (A) Relative distribution of HCP during Protein A chromatog-
raphy, protein ratios (x axis) are calculated from individual peptide 
intensity values divided by the mean of all intensities. The y axis repre-
sents the number of ratios within the bin size of 0.2. The heavy and 
light chains are indicated with blue arrows. (B) Heatmap rows repre-
sent individual proteins identified and relatively quantified by three or 
more peptides, columns represent the individual samples. The intensi-
ty scale: green, black, red, where green indicates relative decrease and 
red increase in protein level with row Z score information. (C) Heat-
map rows represent individual proteins identified and relatively quanti-
fied by three or more peptides, columns represent the individual sam-
ples. The intensity scale: green, black, red, where green indicates rela-
tive decrease and red increase in protein level with row z score infor-
mation. The mAb heavy and light chains are present in the top rows of 
the heatmap.
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risk proteins, such as cytokines that are secreted by 
CHO cells [38]. 
In order to address this, a number of studies on the 
specific identification of HCPs throughout culture and 
during different aspects of the downstream processing of 
recombinant protein molecules (largely mAbs) produced 
in CHO cells [7] now have been reported. For example, a 
previous study investigating CHO HCPs that are difficult 
to remove, used iTRAQ and 2D-PAGE during prolonged 
cultures of CHO cells and identified 92 HCPs that showed 
changes in expression across 500 days of culture over 
which the HCP profile was investigated, with 92% of 
these detected using the iTRAQ shotgun proteomics 
approach, and only 18% by the 2D-PAGE approach, whilst 
11% were detected by both approaches [28]. We, there-
fore, applied an iTRAQ approach to determine the HCP 
profile in the HCCF of a 100 L CHO mAb culture and fol-
lowed this during a subsequent 3-step downstream puri-
fication process.
We identified 819 proteins in the HCCF using iTRAQ 
analysis, including many of the proteins previously identi-
fied in other studies. For identification of proteins, we 
applied a threshold of a minimum of three peptides per 
protein as described in the Methods section and Support-
ing information for identification confidence and to ensure 
that quantification statistics would be reliable. We note 
that this would certainly increase false negatives, but we 
wanted a balance between quantification reliability and 
the loss of a small amount of information on potentially 
interesting HCPs that might have been identified by one 
or two peptides, hence reducing the number of proteins 
we identified in the HCCF and subsequent downstream 
processing steps. We also note that as mass spectrometry 
instruments continue to develop so does sensitivity, and 
with this the number of proteins identified would be 
expected to increase but potentially the reproducibility of 
identifying lower abundance proteins may decrease. This 
should be considered when using any mass spectrometry 
approaches whilst for iTRAQ specifically the reported 
dynamic range of iTRAQ technology and the potential 
signal-to-noise limitations was described previously by 
ourselves [39].
Other reported LC-MS/MS studies of CHO HCPs have 
identified about 1000 proteins across supernatant samples 
from three null cell lines [16], whilst Zhang and colleagues 
used two-dimensional liquid chromatography/mass spec-
trometry to identify approximately 500 HCPs in the cell 
culture fluid of a mAb producing cell line, suggesting that 
the limit of detection for an individual HCP was ~13 ppm 
[24]. Interestingly, Yuk et al. concluded that the difference 
in the HCP profile (and, therefore, the feedstock entering a 
potential downstream process) between the supernatant 
of different null cell lines was not as diverse as might be 
expected [16] and, hence, the DSP and target product is 
pivotal in determining those HCPs that remain at the end 
of any subsequent downstream process. However, others 
have shown that the HCP profiles and amounts do change 
with culture viability [29] that can influence the final HCP 
profile. It should be noted that the difficulty in recovering 
HCPs from cell culture supernatant is not trivial and 
reports have shown that differences in the approaches 
taken to prepare samples can influence the subsequent 
results and coverage of HCPs obtained [27]. 
We then applied the iTRAQ analysis to follow the fate 
of the CHO HCPs during a subsequent model mAb chro-
matographic purification process. Previous reports have 
shown that LC-MS/MS approaches detected 19 HCPs 
from a mAb preparation when combined with an enrich-
ment strategy, as compared to one HCP without the 
enrichment strategy [20]. Zhang et al. also used mass 
spectrometry approaches to monitor HCPs in a Protein A 
eluate pool and, in some cases, beyond, reporting that no 
individual HCPs could be detected in the final cation-
exchange chromatography eluate pools of their purifica-
tion process [24]. We initially utilized Protein A affinity 
followed by cation exchange chromatography, which is 
often used in a mAb purification process, in a bind and 
elute mode, to remove remaining product aggregates, 
HCPs, DNA and leached Protein A. Anion exchange was 
used as a final polishing step, operated in flow-through 
mode, whereby the mAb product does not bind the resin 
but impurities such as HCPs and DNA do. It is well docu-
mented that specific HCPs interact with target mAb 
molecules and Protein A resins and so are retained or co-
purified with the target molecule, and a number of spe-
cific HCPs that associate with resins and mAbs have been 
identified (e.g. [15, 40–44]). As the purification proceeds, 
the concentration of total and, thus of individual, HCPs is 
dramatically reduced and this is set against a background 
where the product mAb concentration may be in the 
10–100s mg/mL. Despite this, we could detect the pres-
ence of HCPs throughout the DSP investigated, even at 
the end of the three-step purification process. As reported 
in other studies, the majority of the detected HCPs were 
a subset of intracellular proteins. However, in contrast to 
other studies (e.g. [24]), we were able to detect these 
throughout the purification process. Our results, as 
emphasized by the heatmaps that track the fate of HCPs 
throughout the purification process (Figs. 4 and 5), show 
that the chromatographic process was successful in 
reducing the total amount, but not all, HCPs.
Our analyses, therefore, show that there is a dynamic 
range of HCPs present in the HCCF of our model CHO-S 
mAb producing cell line and that the majority of the HCPs 
are present throughout the purification process. This was 
initially surprising, as the commercial HCP ELISA sug-
gested the clearance or removal of the majority of HCPs. 
The iTRAQ data give some indication as to those HCPs 
that are likely to be present in the highest amounts at the 
end of the purification process. Those HCPs persisting or 
remaining at higher concentrations at the end of the pro-
cess might be considered critical HCPs that should be 
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carefully monitored and risk assessed. However, simply 
being present is not sufficient to classify these proteins as 
critical, as many doses of therapeutic protein have now 
been administered without reported adverse effects 
directly related to the presence of specific HCPs. Addi-
tional information on the specific HCPs should be consid-
ered, such as their potential immunogenicity, using 
approaches to predict immunogenicity [12] or identifying 
components that may be highly active in the body at low 
concentrations, such as cytokines [10]. HCPs that may be 
detrimental to the target recombinant product itself may 
also be identified and, in this regard, it is of note that 
cathepsins and serine protease HCPs were identified in 
the downstream process, each class of which has been 
reported in the literature to be problematic and have 
resulted in specific target product degradation [32, 33, 
45].
The data we present here provide a comprehensive 
mapping of the CHO HCP at harvest and during a subse-
quent downstream process. Such data sets provide 
knowledge of those HCPs that are removed or reduced in 
amounts via specific chromatographic steps and those 
that are retained, either via interaction with the resin, or 
the mAb itself. By profiling the CHO-S HCP proteome at 
harvest, and following the fate of these HCPs through 
downstream processing, the results of this study can be 
used to help ‘design’ new purification approaches trying 
to reduce specific HCPs and to design assays specific for 
those critical HCPs. A number of studies are now emerg-
ing demonstrating how the HCP profile of sister clones 
can be very similar [16–17], and even in null cell lines of 
different CHO lineages there are remarkable similarities, 
suggesting that the findings from this study in CHO-S are 
likely to have relevance to other CHO systems. Those 
critical HCPs will largely be product specific, however the 
development of new, rapid, analytical technologies based 
upon the knowledge of critical HCPs would be a step for-
ward in the development of bioprocesses and purification 
workflows [19], ultimately leading to improved process 
performance, more reproducible control of HCP amounts 
and an ability to assess the ‘risk’ of HCPs, and assurance 
of product quality.
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